Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) EBITDA Margin (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed EBITDA Margin for 9 consecutive years, with 677.09% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 63625.0% to 677.09% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 343.63% through Dec 2025, down 35732.0% year-over-year, with the annual reading at 343.63% for FY2025, 35714.0% down from the prior year.
  • EBITDA Margin hit 677.09% in Q4 2025 for Protagonist Therapeutics, up from 985.17% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 230.49% in Q4 2023 to a low of 4604.78% in Q2 2022.
  • Historically, EBITDA Margin has averaged 704.11% across 5 years, with a median of 408.85% in 2021.
  • Biggest five-year swings in EBITDA Margin: tumbled -1007971bps in 2021 and later surged 39711bps in 2022.
  • Year by year, EBITDA Margin stood at 429.57% in 2021, then skyrocketed by 92bps to 32.46% in 2022, then soared by 810bps to 230.49% in 2023, then plummeted by -118bps to 40.84% in 2024, then tumbled by -1558bps to 677.09% in 2025.
  • Business Quant data shows EBITDA Margin for PTGX at 677.09% in Q4 2025, 985.17% in Q3 2025, and 758.04% in Q2 2025.